Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Enterprise Registration, Froedtert Health, Menomonee Falls, Wisconsin.
J Surg Res. 2023 Aug;288:269-274. doi: 10.1016/j.jss.2023.03.013. Epub 2023 Apr 8.
Insurance prior authorization (PA) is a determination of need, required by a health insurer for an ordered test/procedure. If the test/procedure is denied, a peer-to-peer (P2P) discussion between ordering provider and payer is used to appeal the decision. The objective of this study was to measure the number and patterns of unnecessary PA denials.
This was a retrospective review at a quaternary cancer center from October 2021 to March 2022. Included were all patients with outpatient imaging orders for surgical planning or surveillance of gastrointestinal, endocrine, or skin cancer. Primary outcome was unnecessary initial denial (UID) defined as an order that required preauthorization, was initially denied by the insurer, and subsequently overturned by P2P.
Nine hundred fifty seven orders were placed and 419 required PA (44%). Of tests requiring authorization, 55/419 (13.1%) were denied. Variability in the likelihood of initial denial was seen across insurers, ranging from 0% to 57%. Following P2P, 32/55 were overturned (58.2% UID). The insurers most likely to have a UID were Aetna (100%), Anthem (77.8%), and Cigna (50.0%). UID was most common for gastrointestinal (58.9%) and endocrine (58.3%) cancers. Average P2P was 33.5 min (interquartile range 28-40).
The majority of imaging studies initially denied were overturned after P2P. If all UIDs were eliminated, this would represent 108 less P2P discussions with an estimated time-savings of 60.3 h annually within a high-volume surgical oncology practice. Combined personnel costs to the health systems and stress on patients with cancer due to image-associated PAs and P2P appear hard to justify.
保险预授权(PA)是健康保险公司对已订购的检查/程序进行需求确定的一种要求。如果该检查/程序被拒绝,将由订单提供者和付款人进行同行对同行(P2P)讨论,以对该决定提出申诉。本研究的目的是衡量不必要的 PA 拒绝数量和模式。
这是 2021 年 10 月至 2022 年 3 月在一个四级癌症中心进行的回顾性研究。纳入标准为所有进行门诊影像检查以进行手术计划或胃肠道、内分泌或皮肤癌监测的患者。主要结果是不必要的初始拒绝(UID),定义为需要预授权的订单,最初被保险公司拒绝,随后被 P2P 推翻。
共下达了 957 项订单,其中 419 项(44%)需要 PA。在需要授权的检查中,55/419(13.1%)被拒绝。不同保险公司之间初始拒绝的可能性存在差异,范围从 0%到 57%。在 P2P 之后,32/55 项(58.2% UID)被推翻。最有可能出现 UID 的保险公司是 Aetna(100%)、Anthem(77.8%)和 Cigna(50.0%)。UID 最常见于胃肠道(58.9%)和内分泌(58.3%)癌症。平均 P2P 时间为 33.5 分钟(四分位距 28-40)。
大多数最初被拒绝的影像学研究在 P2P 后被推翻。如果消除所有 UID,这将代表在一个高容量的外科肿瘤学实践中,每年减少 108 次 P2P 讨论,并节省 60.3 小时。由于与影像相关的 PA 和 P2P,给医疗系统带来的人员成本以及给癌症患者带来的压力,似乎难以证明其合理性。